Mr. Sullivan has over twelve years of operating experience in
the health care industry, with a focus on medical devices and biotechnology.
Before joining Foundation, he helped start Molecular Staging Inc., a
biotechnology company spun out of the Yale School of Medicine that he joined as
the first full-time employee. He served as Director of Business Development
until the successful sale of the company to Qiagen, GmbH. Following this, he
served as a consulting entrepreneur for a variety of early stage healthcare
technology companies, with a particular emphasis on business strategy and
product development. Prior to his entrepreneurial experiences, Mr. Sullivan led
the development of the first coronary stent at Boston Scientific Corporation. He
began his career developing marketing strategies for Johnson & Johnson while
working for Saatchi & Saatchi Advertising. His current or recent board seats
include Semprus BioSciences (acquired by Teleflex, NYSE: TFX) and Direct Flow
Medical, as well as a board observer role at BridgePoint Medical (acquired by
Boston Scientific Corporation, NYSE: BSX). Mr. Sullivan holds a B.S. in
Industrial Engineering degree with distinction from Stanford University and an
M.B.A. from the Stanford University Graduate School of Business.
